Market & Trends

The current global BioPharma market size is US $413Bn (2024) and is expected to reach US $566Bn by 2032: a robust growth rate of 8.6% (CAGR) (US, Canada, EU 80%)
  • Biopharma companies in the USA, Europe and Asia-Pacific are now more frequently outsourcing their resource and capital-intensive manufacturing and development steps (and, in some cases, their entire chain of biomanufacturing) to CMOs and CDMOs, thereby boosting demand for contract-based services in both manufacturing and development.
  • Increasingly, the global biopharmaceutical industry is relying on US FDA and EU EMA approved CMOs and CDMOs to expand their business and stay competitive in biopharma markets. CMOs and CDMOs that can offer integrated bioprocessing services to their clients are very attractive to the Tier 1 clients
  • Biologics market size: USD $284B (2023) (global); (US, Canada, EU = 80%) 
  • Biologics CDMO market size: USD $30.2B (2023) is expected to grow to USD $69B (2032) (US, Canada EU = 90%). CAGR 16.2%
Image
Image
Image
Image